Moderna’s flurry of updates from its Vaccine Day scored well enough with investors as shares rose 6% on Tuesday. The SpikeVax™ developer raised its 2022 sales forecast for the COVID-19 vaccine by 10.5%, from $19 billion to $21 billion, citing Japan’s purchase of 70 million more doses plus the expectation of a sales jump as SARS-CoV-2 becomes endemic by fall/winter . . .
Home Virology Coronavirus GEN Edge StockWatch: Investors Warm to Moderna’s COVID-19 Sales, Vaccine Updates
- Cancer
- Drug Discovery
- Financing
- GEN Edge
- RNA
- mRNA
- Musculoskeletal Disorders
- OMICs
- Renal Cancer
- Vaccine Development
GEN Edge StockWatch: Investors Warm to Moderna’s COVID-19 Sales, Vaccine Updates
NeuroSense quadruples on FDA clearance for oral ALS drug, 4D Pharma shines, while Icosavax and MEI Pharma sink on setbacks
Credit: triloks / Getty Images